Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | SORD | Q00796 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8345923 | 0.84 | MAPT (0.47) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL13680773 | 0.84 | KDM4E (0.52) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL7458233 | 0.84 | MAPT (0.47) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL21346283 | 0.84 | KDM4E (0.47) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL20072401 | 0.81 | MAPT (0.44) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL12589415 | 0.75 | LMNA (0.33) | KDM4EMAPTALDH1A1HSD17B10LMNA | |
| SCHEMBL12589428 | 0.75 | LMNA (0.33) | KDM4EMAPTALDH1A1HSD17B10LMNA | |
| SCHEMBL10293444 | 0.75 | KDM4E (0.33) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL18237977 | 0.75 | CYP2A6 (0.33) | — | |
| SCHEMBL20048894 | 0.75 | NPC1 (0.41) | MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080015212-A1 | Inhibitors Of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-01-17 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| WO-1987007606-A1 | HERBICIDAL SULFONAMIDES | DU PONT (US) | 1987-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | KDM4E 3313/4885MAPT 3828/4885ALDH1A1 112/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | KDM4E 813/4885MAPT 3282/4885ALDH1A1 3007/4885 |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | KDM4E 3908/4885MAPT 227/4885ALDH1A1 945/4885 |
| US-20070043001-A1 | Inhibitors of akt activity | MTMR1, PIK3CA, PLK1 | KDM4E 849/4885MAPT 1276/4885ALDH1A1 3618/4885 |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3CA, PIK3CD, PIK3CB | KDM4E 1558/4885MAPT 3644/4885ALDH1A1 4087/4885 |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | KDM4E 4550/4885MAPT 622/4885ALDH1A1 1372/4885 |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KDM4E 3761/4885MAPT 3027/4885ALDH1A1 4654/4885 |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | KDM4E 3500/4885MAPT 3126/4885ALDH1A1 4328/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KDM4E 3667/4885MAPT 3076/4885ALDH1A1 4633/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | KDM4E 3330/4885MAPT 3830/4885ALDH1A1 111/4885 |
| US-20080015212-A1 | Inhibitors Of Akt Activity | PIK3CA, PIK3CD, PIK3R5 | KDM4E 1609/4885MAPT 4460/4885ALDH1A1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.